| Anxiolytics 2000 Edition Contributor(s): Briley, Mike (Editor), Nutt, David (Editor) |
|
 |
ISBN: 3764360321 ISBN-13: 9783764360320 Publisher: Birkhauser OUR PRICE: $104.49 Product Type: Hardcover - Other Formats Published: September 2000 Annotation: This volume highlights today's and tomorrow's anxiolytics, examining in details the strengths and weaknesses of different classes of proposed anxiolytics. Each chapter is written by an acknowledged international expert actively working in the field. Essentially intended for researchers in academia and the pharmaceutical industry, the book is also of interest to psychiatrists and medical students interested in this specialty. In addition those in the pharmaceutical industry (strategic marketing, licencing, portfolio management...) who need to be able to foresee future developments in the anxiolytic drug scene will find the insights obtained from this volume to be invaluable. By putting side by side today's and tomorrow's anxiolytics the text underlines the progress made (and sometimes the lack of it) in different areas. After reading this book, the reader should have a good "feeling" of where the anxiolytic field is going in the next few years. |
| Additional Information |
| BISAC Categories: - Medical | Pharmacology - Medical | Psychiatry - General - Medical | Pain Medicine |
| Dewey: 615.788 |
| LCCN: 00033748 |
| Series: Milestones in Drug Therapy |
| Physical Information: 0.5" H x 6.14" W x 9.21" (1.00 lbs) 181 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi- azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal. |
